SPRY2 and plasma cell myeloma: Similar data were reported for the behavior of multiple myeloma cells that possessed a knock-down in expression of the SPRY2 gene [48] and after pharmacological inhibition of expression of the urokinase-type plasminogen activator in human breast carcinoma cells [49].